Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsModa Health Cerezyme (imiglucerase) Prior Auth | O…
    Ask Trek AI about this page
    CurrentModa HealthPolicy M-0027

    Cerezyme (imiglucerase) (Intravenous) — Coverage Criteria

    Customize your policy alerts

    Sign up for Moda Health Policy M-0027 alerts

    Get alerted when Policy M-0027 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing prior authorization, dosing limits, indications, and renewal criteria for intravenous Cerezyme (imiglucerase) for members covered by Moda Health.

    Policy Summary
    PayerModa Health
    PolicyCerezyme (imiglucerase) (Intravenous) — Coverage Criteria
    Policy CodePolicy M-0027
    Change TypeNo material change
    Effective DateFeb 3, 2026
    Last ReviewFeb 3, 2026
    Next Review DateFeb 3, 2026
    Key ActionObtain prior authorization valid for 12 months before initiating or renewing Cerezyme therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsprior auth validity
    720max HCPCS units /14d
    J1786HCPCS code
    E75.22ICD-10
    1

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ICD-10 codes listed

    Coverage Criteria

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Universal requirements: Site of care specialty infusion program requirements are met (refer to Moda Site of Care Policy); drug is used as a single agent.

    Initial authorization provided for 12 months

    Diagnostic confirmation: Documented diagnosis of Type 1 or Type 3 Gaucher disease confirmed by one of the following: significantly reduced or absent glucocerebrosidase enzyme activity as measured by a beta-glucosidase leukocyte (BGL) test, OR detection of mutations in the glucocerebrosidase (GBA) gene.
    Clinical manifestation requirement: Presence of one or more non‑central nervous system (non‑CNS) manifestations of Type 1 or Type 3 Gaucher disease, defined as one or more of: anemia‑related symptoms (e.g., transfusion dependency or hemoglobin ≤11 g/dL in women/children or ≤12 g/dL in men), thrombocytopenia (platelet count ≤120,000/mm3), hepatomegaly or splenomegaly, skeletal disease (e.g., lesions, remodeling defects, osteopenia/osteoporosis), or symptomatic disease (e.g., bone pain, fatigue, dyspnea, abdominal distension, diminished quality of life).
    Dosing/limits: Initial dosages range from 2.5 U/kg IV three times weekly to 60 U/kg IV once every 2 weeks and should be titrated based on disease severity and therapeutic goals; maximum policy limit is 720 billable HCPCS units every 14 days (1 billable unit = 10 units; HCPCS J1786).720 units per 14 days

    Verify billing using J1786 where 1 billable unit = 10 units

    Continuation/Renewal — Renewal requires ALL of the following

    Renewal (continued coverage) requires ALL of the following:

    Ongoing eligibility: Patient continues to meet the universal and indication‑specific criteria identified for initial therapy (see Initial Therapy criteria).

    Renewal prior authorization may be provided for 12 months

    Safety: Absence of unacceptable toxicity from the drug. Examples include severe hypersensitivity reactions (including anaphylaxis) or severe infusion‑associated reactions (e.g., angioedema, pruritus, rash, urticaria, chest discomfort, chills, fatigue, infusion‑site burning/discomfort/swelling, pyrexia, hypertension).

    If a severe hypersensitivity or severe IAR occurs, discontinue CEREZYME and initiate appropriate medical treatment; for mild/moderate reactions consider infusion rate adjustment or supportive medications.

    Evidence of benefit: Demonstrated disease response compared to pretreatment baseline as shown by one or more of: improvement in anemia‑related symptoms (improved hemoglobin and/or decreased transfusion dependency), improvement in platelet counts, reduction in liver or spleen size, improvement in skeletal disease (e.g., increased BMD, no bone crises/fractures), or improvement in symptoms (e.g., bone pain, fatigue, dyspnea, abdominal distension, quality of life).

    If a member experiences a severe hypersensitivity reaction (e.g., anaphylaxis) or a severe infusion-associated reaction (IAR) during CEREZYME (imiglucerase) administration, the drug must be discontinued immediately and appropriate medical treatment initiated. For mild to moderate hypersensitivity or IARs, consider slowing or temporarily stopping the infusion and administering supportive therapies such as antihistamines, antipyretics, and/or corticosteroids as clinically indicated.

    Coding and Billing

    Covered HCPCS CodesHCPCSCovered
    J1786Injection, imiglucerase, 10 units; 1 billable unit = 10 units
    Relevant NDCsNDC
    58468-4663-xxCerezyme 400 unit powder for injection, single-dose vial
    Covered Diagnosis Codes (ICD-10)ICD-10Covered
    E75.22Gaucher disease
    Covered ICD-10 CodesICD-10Covered
    E75.22Gaucher disease
    Medicare Part B Covered Diagnosis CodesICD-10
    No codes listed
    Maximum HCPCS units
    Maximum HCPCS units720 billable units every 14 days
    HCPCS unit definition1 billable unit = 10 units (J1786)
    Limit intervalMeasured over a 14-day period

    Provider Actions and Requirements

    Prior Authorization

    Obtain prior authorization for 12 months

    Prior authorization is required for Cerezyme (imiglucerase). Initial authorizations are provided for 12 months (365 days) and renewals may be issued every 12 months (365 days).

    Note

    Verify Medicare coverage determinations before billing

    For Medicare Part B claims, verify and comply with any applicable CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), or Local Coverage Articles (LCAs) and follow jurisdictional guidance when submitting outpatient drug claims.

    • Search for applicable NCD/LCD/LCA at the CMS Coverage Database: https://www.cms.gov/medicare-coveragedatabase/search.aspx
    Step Therapy

    Background

    Gaucher disease (Type 1 or Type 3) is an inherited lysosomal storage disorder caused by deficient glucocerebrosidase activity. Enzyme replacement therapy with imiglucerase (Cerezyme) replaces the deficient enzyme to reduce non‑CNS manifestations such as anemia, thrombocytopenia, hepatosplenomegaly, skeletal disease, and related symptoms. Diagnosis should be confirmed by markedly reduced or absent glucocerebrosidase activity or by identification of pathogenic GBA gene mutations; treatment decisions and dosing are guided by disease severity and therapeutic goals, with dosing ranges from low‑dose regimens up to higher intermittent dosing and a policy maximum quantity limit of 720 billable HCPCS units every 14 days (HCPCS code J1786, where 1 billable unit = 10 units). Prior authorization is required and initial and renewal approvals are typically valid for 12 months.

    Definitions

    Non-CNS manifestations
    Anemia-related symptomsBlood transfusion dependency and/or hemoglobin ≤11 g/dL (women and children) or ≤12 g/dL (men)
    ThrombocytopeniaPlatelet count ≤120,000/mm3
    Hepatomegaly or splenomegalyEnlargement of liver or spleen documented on exam or imaging
    Skeletal diseaseLesions, remodeling defects/deformity of long bones, osteopenia/osteoporosis, etc.
    Symptomatic diseaseClinical symptoms such as bone pain, fatigue, dyspnea, abdominal distension, or diminished quality of life
    E75.22 — ICD-10 mapping
    ICD-10 code

    Initial Therapy Dosing and Criteria

    Initial Dosing

    Initial dosages and policy limits:

    Dose range: Initial dosages range from 2.5 U/kg IV three times weekly to 60 U/kg IV once every 2 weeks; titrate based on disease severity and therapeutic goals.720 units per 14 days

    1 billable HCPCS unit = 10 units (HCPCS J1786)

    Continuation and Renewal Criteria

    Renewal Criteria

    Renewal (prior authorization renewal) requires continued documentation of all of the following:

    Renewal nodes: Ongoing fulfillment of the initial therapy universal and indication-specific criteria; absence of unacceptable toxicity (e.g., severe hypersensitivity or severe infusion-associated reactions); and objective or clinical evidence of disease response compared to pretreatment baseline (hematologic improvement, improved platelet counts, reduction in liver/spleen size, improvement in skeletal disease or symptoms).

    Renewal authorization may be valid for 12 months

    Step Therapy

    StepRequirement
    1No prerequisite therapy required; medication must be used as a single agent.

    Quantity Limits

    imiglucerase (Cerezyme) — Quantity limits
    Productimiglucerase (Cerezyme)
    Quantity limit720 billable HCPCS units per 14 days
    Billing code (unit basis)HCPCS J1786 — Injection, imiglucerase, 10 units; 1 billable unit = 10 units

    Site of Care

    Note

    Use approved specialty infusion program site of care

    Administer Cerezyme in a site-of-care that meets Moda’s specialty infusion program requirements as referenced in the Moda Site of Care Policy.

    • Confirm infusion center participation in Moda’s specialty infusion program before authorizing treatment
    Policy Summary
    PayerModa Health
    PolicyCerezyme (imiglucerase) (Intravenous) — Coverage Criteria
    Policy CodePolicy M-0027
    Change TypeNo material change
    Effective DateFeb 3, 2026
    Last ReviewFeb 3, 2026
    Next Review DateFeb 3, 2026
    Key ActionObtain prior authorization valid for 12 months before initiating or renewing Cerezyme therapy.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Actions and RequirementsBackgroundDefinitionsInitial Therapy Dosing and CriteriaContinuation and Renewal CriteriaStep TherapyQuantity LimitsSite of Care

    Use as single‑agent therapy (no step prerequisites)

    Use Cerezyme as a single agent; no prerequisite step‑therapy agents are specified in this policy.

    Note

    Verify site‑of‑care specialty infusion program requirements

    Confirm site‑of‑care meets Moda’s specialty infusion program requirements when requesting authorization and delivering therapy.

    • Refer to the Moda Site of Care Policy for program requirements.
    Documentation Required

    Submit required clinical and billing documentation

    Include documentation confirming Type 1 or Type 3 Gaucher disease and supporting clinical/laboratory evidence when requesting authorization or submitting claims.

    • Confirmation by significantly reduced or absent glucocerebrosidase activity (beta‑glucosidase leukocyte [BGL] test) or detection of GBA gene mutations
    • Documentation of non‑CNS manifestations (e.g., anemia-related symptoms, thrombocytopenia ≤120,000/mm3, hepatomegaly/splenomegaly, skeletal disease, symptomatic disease)
    • Dosing information consistent with policy limits and HCPCS/NDC billing details
    Billing Rule

    Bill with diagnosis code E75.22

    Use ICD‑10 code E75.22 (Gaucher disease) on claims for Cerezyme.

    Denial Risk

    Renewal may be denied for toxicity or lack of response

    Renewal requests may be denied if the member has unacceptable toxicity (for example, severe hypersensitivity or severe infusion‑associated reactions) or if renewal criteria (ongoing meeting of initial criteria and evidence of disease response) are not met.

    • Examples of unacceptable toxicity include anaphylaxis and severe infusion‑associated reactions (angioedema, urticaria, chest discomfort, chills, pyrexia, etc.)
    • Renewal requires absence of unacceptable toxicity and objective or clinical evidence of response compared to pretreatment baseline
    Note

    Ensure Medicare policy compliance to avoid denials

    Medicare claims must comply with applicable NCDs, LCDs, or LCAs and any related jurisdictional guidance; failure to follow applicable Medicare policy may result in claim denial.

    • This document governs non‑Medicare determinations; for Medicare Part B follow the Medicare Benefit Policy Manual Chapter 15 §50 and applicable NCD/LCD/LCA guidance
    E75.22
    DescriptionGaucher disease